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Abstract
Pulmonary hypertension (PH) type II (classiﬁed by the World Health Organization) is a common complication in chronic left-
sided heart failure. In advanced heart failure therapy, ﬁxed PH is an absolute contraindication for heart transplantation after
which a left ventricular assist device (LVAD) is the only remaining option. With remote monitoring, we can now continuously
evaluate the pulmonary artery pressures during long-term LV unloading by the LVAD. In this case, we demonstrate that ﬁxed
PH can be reversed with LVAD implantation, whereby previous thoughts of this concept should be redeﬁned in the era of assist
devices.
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Introduction
In patients with chronic left-sided heart failure (HF), pulmo-
nary hypertension (PH) (classiﬁed by the World Health Orga-
nization as group 2) is a common complication.1 PH occurs in
up to 60% of the patients with severe left ventricular systolic
dysfunction, and up to 70% in patients with HF with pre-
served ejection fraction.2 HF causes chronic pulmonary con-
gestion, resulting in elevated pulmonary capillary wedge
pressure (PCWP). The right ventricle (RV) adapts slowly over
time in order to overcome the increasing PCWP, leading to in-
creasing pulmonary artery pressures (PAPs). Over time, this
process results in pulmonary capillary and arterial remodel-
ling. The vascular wall stiffens and loses its elasticity and abil-
ity to compensate for the higher pressures, resulting in
elevated pulmonary vascular resistance (PVR). Additionally,
several pulmonary diseases affect the PVR and cause PH. At
screening for candidacy for heart transplantation (HTx), the
standard procedure is to perform a right heart catheteriza-
tion (RHC) to study these aspects in detail. If at the Swan–
Ganz measurement the patient has PH, we perform a vasodi-
lator test to evaluate the reversibility of PH and PVR. Revers-
ibility is crucial in potential HTx candidates. Because the RV of
the donor heart will not be capable to build up PAPs to over-
come the ﬁxed high PVR, after a period of stunning by ische-
mia, the RV is most likely to fail immediately. Left ventricular
assist device (LVAD) therapy can be successful in lowering
PAPs by unloading the left ventricle, which will aid in the
treatment of PH caused by left-sided heart disease.3 How-
ever, limited data are available on the topic whether ﬁxed
PH can be reversed as well. The acute and chronic effects
of LVAD therapy on PH have not been clearly investigated.
The recently introduced CardioMEMS sensor offers the possi-
bility to study this concept, because it allows for remote daily
monitoring of PAPs, even in LVAD patients,4 as we have
shown in our case.
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Case report
A 53-year-old man with a history of severe dilated cardiomy-
opathy was admitted with progressive HF, despite maximal
tolerated medical therapy. During the admission, the patient
was screened for both HTx and LVAD implantation. The RHC
revealed a cardiac output of 3.8 L/min, PAP 61/31 mmHg
(mean 43), PCWP 28 mmHg, and PVR 316 dynes/s/cm5 (3.9
Woods). During the vasodilator test of reversibility, intrave-
nous nitroglycerin was up-titrated to maximum tolerated dos-
age (100 μg/min) without inducing systemic hypotension; PAP
[47/23 mmHg (34)], PCWP (20 mmHg), and the PVR (295
dynes/s/cm5, 3.7 Woods) remained elevated, conﬁrming the
diagnosis of ﬁxed PH. In the multidisciplinary heart team, the
patient was rejected as candidate for HTx owing to irreversible
PH and was accepted for LVAD (HeartMate 3, Abbott Inc, At-
lanta, GA, USA) as bridge to transplant or destination therapy.
A CardioMEMS device was implanted, followed by LVAD im-
plantation 2 weeks later. Post-operatively, the LVAD support
provided additional room for further up-titration of the medi-
cal therapy. Echocardiography and PAPs were used to up-
titrate renin–angiotensin system inhibition, mineralocorticoid
receptor antagonist, and diuretics and the LVAD speed set-
tings. The patient recovered well with an uncomplicated
course and was discharged home.
In the outpatient setting, haemodynamic feedback pro-
vided by the CardioMEMS was used for further treatment op-
timization. A combination of hydralazine/isosorbide dinitrate
was started and slowly up-titrated resulting in a small decline
in PAP. However, this was limited owing to complaints of dizziness.
Approximately 160 days after LVAD implantation, the patient
was admitted owing to dehydration and hypotension due to in-
sufﬁcient intake, which was identiﬁed by the sudden drop in
PAPs. During admission, antihypertensive medication and di-
uretics had to be lowered or stopped, allowing the renal func-
tion to recover. After discharge, medication was up-titrated
again tomaximum tolerated dosage, limited oncemore by com-
plaints of dizziness. Even though further up-titration of medica-
tion was not possible, the mean PAP (mPAP) continued to
decline gradually and then ﬁnally normalized. Approximately
290 days post-LVAD implantation, a consistent mPAP < 25
mmHg was reached. During follow-up, the patient regularly
underwent echocardiography, demonstrating a stable RV func-
tion and only a minor tricuspid valve regurgitation, suggesting
that the decline in mPAP was caused by reversibility of the
‘ﬁxed’ PHandwas not due to a decline in RV function. Currently,
the candidacy for HTx is re-evaluated, and likely no cardiac is-
sues will be raised for acceptance on the waiting list.
Discussion
This case report demonstrates for the ﬁrst time the continu-
ous follow-up of PAP data in a LVAD patient with ﬁxed PH, for
up to 300 days post-LVAD implantation. This case demon-
strates that LVAD therapy is a successful treatment for lower-
ing PAP in patients with ﬁxed PH, additional to optimal
medical treatment. The reversibility of PH and candidacy for
HTx thereby become a more dynamic state, which changes
views on these programmes in light of expanding LVAD
programmes.
The increase of left ventricular ﬁlling pressure leads to an
increase in post-capillary pressure and elevated PCWP in the
pulmonary circulation. This leads to endothelial dysfunction,
making the vascular walls less ﬂexible owing to smooth
muscle cell hypertrophy and hyperplasia, increasing the
PVR. Thereby, PH arises, followed by remodelling of the ar-
terial wall. This is characterized by medial hypertrophy and
intimal ﬁbrosis. Longstanding PH can grow to a state of
ﬁxed PH. Current data are conﬂicting about the reversibility
of severe or ﬁxed PH, with some data suggesting that LVAD
therapy can reverse ﬁxed PH. However, it remains unclear
whether this is caused by remodelling of the pulmonary vas-
cular wall or LV unloading and remodelling. Furthermore,
the cut-off between ﬁxed and reversible PH is unclear, and
there is no agreement on the time needed to reach
irreversibility.5
Continuous-ﬂow LVADs unload the left ventricle and lower
the cardiac ﬁlling pressures. As has been shown previously,
LVAD therapy is more effective in treating ‘ﬁxed’ PH than is
maximal medical therapy.3,5 The CardioMEMS device allows
for daily PAP readings (Figure 1) and was used to observe
the haemodynamic changes after medication changes. As
shown in this case, up-titrating the medical therapy to maxi-
mal tolerated dosage did not lead to a normalization of the
PAPs. However, as shown, during the longer-term follow-up,
the PAPs slowly declined, and after 0.5 to 1 year of LVAD sup-
port, the PAPs normalized with an mPAP < 25 mmHg. These
results show the natural decline of PAP while on LVAD sup-
port besides the haemodynamic effects of maximal tolerated
medical therapy.
Previous studies investigating the reversibility of ﬁxed PH
were limited to repeated invasively measured PAP readings,
instead of continuous PAP readings. So the timing of revers-
ibility of ﬁxed PH is still unclear.
Mikus et al. investigated the reversibility of PH during
LVAD support at 6, 12, and 18 months of follow-up and
concluded that the biggest reduction in PAP will occur
within the ﬁrst 6 months post-LVAD implantation.5 In con-
trast, our case shows a slow decline in PAP over time in
which the PAP of our patient normalized only after 300
days on LVAD support. This result suggests that the decline
of PAP can occur past the 6 months suggested in the previ-
ous study.
Reversibility of ﬁxed PH is very important because ﬁxed PH
is a contraindication for HTx. When HTx is performed in a pa-
tient with ﬁxed PH, the stunned RV of the donor could not
overcome the high afterload and fails owing to elevated
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PVR. RV failure is a major cause of both mortality and morbid-
ity after LVAD implantation as well (20–50% of patients).6 By
lowering PAP, there is more potential to improve or maintain
RV function at long-term LVAD support, which is essential, es-
pecially in destination therapy. This could help in the long-
term survival of LVAD patients who depend on a good work-
ing RV for a proper functioning LVAD. This case demonstrates
that the haemodynamic feedback, provided by the
CardioMEMS, can be used to optimize medical therapy also
in LVAD patients. And this provides feedback on haemody-
namic changes, which could help to detect problems such
as dehydration or decompensation in earlier stages.
Conclusions
Continuous-ﬂow LVAD can reverse ﬁxed PH, even after a pe-
riod of 6 months on LVAD support. The CardioMEMS sensor
enables to monitor and guide the treatment of PH in patients
with an LVAD and severe PH.
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Figure 1 Daily pulmonary artery pressure readings and medication changes. LVAD, left ventricular assist device; MRA, mineralocorticoid receptor an-
tagonist; PA, pulmonary artery; RAS, renin–angiotensin system.
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